

1. Baby K, Maity S, Mehta CH, Nayak UY, Shenoy GG, Pai KSR, **Harikumar KB**, Nayak Y. Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer (2023). **Scientific Reports.** 13(1):7947.
2. Suresh D, Srinivas AN, Prashant A, **Harikumar KB**, Kumar DP (2023). Therapeutic options in hepatocellular carcinoma: a comprehensive review. **Clinical and Experimental Medicine.** 23(6):1901-1916.
3. Beena TB, Jesil MA, **Harikumar KB** (2023). Cross-talk between AMP-activated protein kinase and the sonic hedgehog pathway in the high-fat diet triggered colorectal cancer. **Archives of Biochemistry and Biophysics.** 735:109500.
4. Swetha M, Keerthana CK, Rayginia TP, Nath LR, Haritha NH, Shabna A, Kalimuthu K, Thangarasu AK, Aiswarya SU, Jannet S, Pillai S, **Harikumar KB**, Sundaram S, Anto NP, Wu DH, Lankalapalli RS, Towner R, Isakov N, Deepa SS, Anto RJ (2022). Augmented efficacy of Uttroside B over sorafenib in a murine model of human hepatocellular carcinoma. **Pharmaceuticals (Basel).** 15(5):636.
5. Arndt C, Bergmann R, Striese F, Merkel K, Máthé D, Loureiro LR, Mitwasi N, Kegler A, Fasslirinner F, González Soto KE, Neuber C, Berndt N, Kovács N, Szöllősi D, Hegedűs N, Tóth G, Emmermann JP, **Harikumar KB**, Kovacs T, Bachmann M, Feldmann A (2022). Development and functional characterization of a versatile radio-/immunotheranostic tool for prostate cancer management. **Cancers (Basel).** 14(8):1996.
6. Manu KA, **Harikumar KB**, Ishimoto T (2022). Editorial: Targeting pancreatic cancer: strategies and hopes. **Frontiers in Oncology.** 12:873682.
7. Kurani H, Razavipour SF, **Harikumar KB**, Dunworth M, Ewald AJ, Nasir A, Pearson G, Van Booven D, Zhou Z, Azzam D, Wahlestedt C, Slingerland J. DOT1L Is a novel cancer stem cell target for triple-negative breast cancer (2021). **Clinical Cancer Research.** 28(9):1948- 1965.
8. James S, Aparna JS, Babu A, Paul AM, Lankadasari MB, Athira SR, Kumar SS, Vijayan Y, Namitha NN, Mohammed S, Reshma G, **Harikumar KB** (2021). Cardamonin attenuates experimental colitis and associated colorectal cancer. **Biomolecules.** 11(5):661.
9. Anu B, Namitha NN, **Harikumar KB**. S1PR1 signaling in cancer: A current perspective (2021). **Advances in Protein Chemistry and Structural Biology.** 125:259-274 (*Highlighted in front cover page*).
10. Avni D, **Harikumar KB**, Sanyal AJ, Spiegel S (2021). Deletion or inhibition of SphK1 mitigates fulminant hepatic failure by suppressing TNFα-dependent inflammation and apoptosis. **The FASEB Journal.** 35(3):e21415.
11. Razavipour SF[#], **Harikumar KB[#]**, Slingerland JM (2020). p27 as a Transcriptional Regulator: New

- roles in development and cancer. **Cancer Research**. 80(17):3451-3458 (# **Equal first author contribution**).
12. Mohammed S, Vineetha NS, James S, Aparna JS, Lankadasari MB, Maeda T, Ghosh A, Saha S, Li QZ, Spiegel S, **Harikumar KB** (2020). Regulatory role of SphK1 in TLR7/9-dependent type I interferon response and autoimmunity. **The FASEB Journal**. 34:4329-4347.
 13. Lankadasari MB, Mukhopadhyay P, Mohammed S, **Harikumar KB** (2019). TAMing pancreatic cancer: combat with a double edged sword. **Molecular Cancer**. 18(1):48. (*Part of 2019 special collection "Microvesicles and tumor microenvironment in cancer development and resistance to therapies"*).
 14. Mohammed S, Vineetha NS, James S, Aparna JS, Lankadasari MB, Allegood JC, Lin QZ, Spiegel S, **Harikumar KB** (2019). Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus. **The FASEB Journal**. 33(6):7061-7071.
 15. Vijayan Y, Lankadasari MB, **Harikumar KB** (2019). Acid ceramidase: A novel therapeutic target in cancer. **Current Topics in Medicinal Chemistry**. 19(17):1512-1520.
 16. Lankadasari MB, Aparna JS, Mohammed S, James S, Aoki K, Binu VS, Nair S, **Harikumar KB** (2018). Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. **Theranostics**. 13;8(14):3824-3840 (*Highlighted in back cover page*)
 17. Rajagopal C, **Harikumar KB** (2018). The origin and functions of exosomes in cancer. **Frontiers in Oncology**. 8:66.
 18. Majumder A, Syed KM, Mukherjee A, Lankadasari MB, Azeez JM, Sreeja S, **Harikumar KB**, Pillai MR, Dutta D (2018). Enhanced expression of histone chaperone APLF associate with breast cancer. **Molecular Cancer**. 17(1):76.
 19. Rajagopal C, Lankadasari MB, Aranjani JM, **Harikumar KB** (2018). Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy. **Pharmacological Research**. 130:273- 291.
 20. James S, Aparna JS, Paul AM, Lankadasari MB, Mohammed S, Binu VS, Santhoshkumar TR, Reshma G, **Harikumar KB** (2017). Cardamonin inhibits colonic neoplasia through modulation of MicroRNA expression. **Scientific Reports**. 24;7(1):13945.
 21. Mohammed S, **Harikumar KB** (2017). Sphingosine 1-Phosphate: A novel target for lung disorders. **Frontiers in Immunology**. 14;8:296.
 22. Oskeritzian CA, Hait NC, Wedman P, Chumanovich A, Kolawole EM, Price MM, Falanga YT, **Harikumar KB**, Ryan JJ, Milstien S, Sabbadini R, Spiegel S (2014). The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. **Journal of Allergy and Clinical Immunology**. 135(4):1008-1018.

23. **Harikumar KB**, Hardman R, Aranjani JM, Raveendran VV, Thejass P (2014). Immunomodulatory activity of complementary and alternative medicines (Editorial) *Evidence Based Complementary and Alternative Medicine*. 2014:765107.
24. **Harikumar KB**, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC, Hait NC, Allegood JC, Yamada A, Kong X, Lazear HM, Bhardwaj R, Takabe K, Diamond MS, Luo C, Milstien S, Spiegel S, Kordula T (2014). K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. *Nature Immunology*. 15:231-238.
25. Liang J, Nagahashi M, Kim EY, **Harikumar KB**, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S, Spiegel S (2013). Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. *Cancer Cell*. 23:107-20.
26. Price MM, Oskeritzian CA, Falanga YT, **Harikumar KB**, Allegood JC, Alvarez SE, Conrad D, Ryan JJ, Milstien S, Spiegel S (2013). A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. *Journal of Allergy and Clinical Immunology*. 131:501-511.
27. Van DN, Roberts CF, Marion JD, Lépine S, **Harikumar KB**, Schreiter J, Dumur CI, Fang X, Spiegel S, Bell JK (2012). Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic therapeutics. *FASEB Journal*. 26:3188-3198.
28. Maceyka M, **Harikumar KB**, Milstien S, Spiegel S (2012). Sphingosine-1-phosphate signaling and its role in disease. *Trends in Cell Biology*. 22:50-60.
29. Yester JW, Tizazu E, **Harikumar KB**, Kordula T (2011). Extracellular and intracellular sphingosine-1-phosphate in cancer. *Cancer and Metastasis Review*. 30:577-597.
30. Alvarez SE#, **Harikumar KB#**, Hait NC, Allegood J, Strub GM, Kim E, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S and Spiegel S (2010). Sphingosine-1-Phosphate: A missing cofactor for the E3 ubiquitin ligase TRAF2. *Nature*. 465:1084-1089. (# Equal first author contribution).
31. **Harikumar KB**, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S and Aggarwal BB (2010). Resveratrol, A multi-targeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. *International Journal of Cancer*. 127:257-268.
32. **Harikumar KB**, Sung B, Tharakan ST, Pandey MK, Joy B, Guha S, Krishnan S, and Aggarwal BB (2010). Sesamin manifests chemopreventive effects through suppression of NF- κ B-regulated cell survival, proliferation, invasion and angiogenic gene products. *Molecular Cancer Research*. 8:751-761.
33. **Harikumar KB**, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S,

- Sutherland R, Raynham T, Charles M, Bagherazadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, and Guha S (2010). A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth *in vitro* and *in vivo*. *Molecular Cancer Therapeutics*. 9:1136-1146. (Selected to issue highlight section of MCT).
34. **Harikumar KB**, Sung B, Pandey MK, Guha S, Krishnan S, and Aggarwal BB (2010). Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of NF- κ B signaling pathway. *Molecular Pharmacology*. 77:818–827.
35. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, **Harikumar KB**, Hait NC, Milstien S, and Spiegel S (2010). Estradiol induces export of sphingosine-1-phosphate from breast cancer cells via ABCC1 and ABCG2. *Journal of Biological Chemistry*. 285:10477– 10486.
36. Anchoori RK, **Harikumar KB**, Batchu VR, Aggarwal BB, and Khan SR (2010). Inhibition of I κ B kinase and NF- κ B by a novel synthetic compound SK 2009. *Bioorganic & Medicinal Chemistry*. 18:229-235.
37. Hait NC, Allegood J, Maceyka M, Strub GM, **Harikumar KB**, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, and Spiegel S (2009). Sphingosine Kinase 2 and S1P in the nucleus regulate histone acetylation by inhibition of histone deacetylases. *Science*. 325:1254-1257.
38. **Harikumar KB**, Kuttan G and Kuttan R (2009). Inhibition of viral carcinogenesis by *Phyllanthus amarus* Schumach & Thonn. *Integrative Cancer Therapies*. 8:254-260.
39. Kunnumakkara AB, Diagaradjane P, Anand P, **Harikumar KB**, Deorukhkar A, Gelovani J, Guha S, Krishnan S, and Aggarwal BB (2009). Curcumin sensitizes human colorectal cancer to capecitabine by modulation of Cyclin D1, COX2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. *International Journal of Cancer*. 125: 2187-2197.
40. **Harikumar KB**, Kuttan G and Kuttan R (2009). *Phyllanthus amarus* inhibits cell growth and induces apoptosis in Dalton's lymphoma ascites cells through activation of caspase 3 and down regulation of Bcl-2. *Integrative Cancer Therapies*. 8:190-194.
41. **Harikumar KB**, Kunnumakkara AB, Ahn KS, Anand P, Krishnan K, Guha S, and Aggarwal BB
42. (2009). Modification of the cysteine residues in I κ B α kinase and NF- κ B (p65) by xanthohumol leads to suppression of NF- κ B-regulated gene products and potentiation of apoptosis in leukemia cells. *Blood*. 113:2003-2013.
43. Aggarwal BB, Kunnumakkara AB, **Harikumar KB**, Gupta SR, Tharakan ST, Koca C, Dey S, and Sung B (2009). STAT-3, inflammation and cancer: How intimate is the relationship? *Annals of the New York Academy of Sciences*. 1171:59-76.
44. Aggarwal B, Van Kuiken ME, Iyer LH, **Harikumar KB**, and Sung B (2009). Molecular targets of

nutraceuticals derived from dietary Spices: Potential role in suppression of inflammation and tumorigenesis. *Experimental Biology and Medicine (Maywood)*. 234:825-849. (Ranked at number 7 in 50 most frequently read article).

45. Aggarwal BB and **Harikumar KB** (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *International Journal of Biochemistry and Cell Biology*. 41:40-59. (Most cited paper during 2008-2010 period).
46. Kunnumakkara AB, **Harikumar KB**, Anand P, Sung B, Ahn KS, Lai SO, Tharakan ST and Aggarwal BB (2008). Targeting inflammation for prevention of cancer by food and food factors. *Journal of Clinical Biochemistry and Nutrition*. Suppl. 43, 1–10.
47. **Harikumar KB**, Kuttan G and Kuttan R (2008). Inhibition of progression of erythroleukemia induced by Friend virus in BALB/c mice by natural products - Berberine, Curcumin and Picroliv. *Journal of Experimental Therapeutics and Oncology*. 7: 275–284
48. Shishodia S, **Harikumar KB**, Dass S, Ramawat KG, and Aggarwal BB (2008). The Guggul for chronic diseases: Ancient medicine, modern targets. *Anticancer Research*. 28:3647-3664.
49. Shakibaei S, **Harikumar KB** and Aggarwal BB (2008). Resveratrol addiction: To die or not to die. *Molecular Nutrition and Food Research*. 53:115-128.
50. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, **Harikumar KB**, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, and Aggarwal BB (2008). Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. *Biochemical Pharmacology*. 76:1590-1611.
51. Aggarwal BB, Kunnumakkara AB, **Harikumar KB**, Tharakan ST, Sung B and Anand P (2008). Potential of spice-derived phytochemicals for cancer prevention. *Planta Medica*. 74:1560-1569.
52. Anand P, Kunnumakara AB, Sundaram C, **Harikumar KB**, Tharakan ST, Lai OS, Sung B and Aggarwal BB (2008). Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceutical Research*. 25:2097-2116.
53. **Harikumar KB** and Aggarwal BB (2008). Resveratrol: a multitargeted agent for age-associated chronic diseases. *Cell Cycle*. 7:1020-1035.
54. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, **Harikumar KB**, Ramachandran V, Sung B, Chakraborty A, Bresalier RS, Logsdon C, Aggarwal BB, Krishnan S, Guha S (2008). Neutrophil gelatinase-associated lipocalin: A novel suppressor of invasion and angiogenesis in pancreatic cancer. *Cancer Research*. 68:6100-6108.
55. **Harikumar KB**, Nimita CV, Preethi KC, Kuttan R, Shankaranarayana ML and Deshpande J (2008). Toxicity profile of lutein and lutein ester isolated from marigold flowers (*Tagetes erecta*).

International Journal of Toxicology. 27:1-9.

56. **Harikumar KB**, and Kuttan R (2007). An extract of *Phyllanthus amarus* protects mouse chromosomes and intestine from radiation induced damages. *Journal of Radiation Research*.
57. **Hari Kumar KB**, Sunila ES, Kuttan G, Preethi KC, Nimita CV and Kuttan R (2007). Inhibition of chemically induced carcinogenesis by potentiated homeopathic drugs. *Asian Pacific Journal of Cancer Prevention*. 8:98-102.
58. Kuttan G, **Hari Kumar KB**, Guruvayoorappan, C and Kuttan R (2007). Anti-tumour, anti invasion and antimetastatic effects of Curcumin. *Advances in Experimental Medicine and Biology*.595:173-184.
59. Raphael RK, Sabu MC, **Hari Kumar KB**, and Kuttan R (2006). Inhibition of N-methyl N'-nitro-Nnitrosoguanidine (MNNG) induced gastric carcinogenesis by *Phyllanthus amarus* extract. *Asian Pacific Journal of Cancer Prevention* 7:299-302.
60. **Hari Kumar KB** and Kuttan R (2006). Inhibitory effect of an extract of *Phyllanthus amarus* on drug metabolizing enzymes in vitro as well as in vivo. *Biological and Pharmaceutical Bulletin*. 29: 1310- 1313.
61. Ajith TA, **Harikumar KB**, Thasna. H, Sabu MC and Babitha NV (2006): Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's Lymphoma Ascites tumor in mice. *Clinica Chimica Acta*. 366: 322-328.
62. **Harikumar KB**, Jesil AM, Sabu MC, Kuttan R (2005). A preliminary assessment of the acute and subchronic toxicity profile of phase2 α : an alpha-amylase inhibitor. *International Journal of Toxicology*. 24:95-102.
63. **Kumar KBH** and Kuttan R (2005): Chemoprotective effect of an extract of *Phyllanthus amarus* against cyclophosphamide induced toxicity in mice. *Phytomedicine*. 12:494-500.
64. **Hari Kumar KB** and Kuttan R (2005). Radioprotective and anticlastogenic activity of *Phyllanthus amarus*. *The Indian Journal of Medical Research*, 121(Suppl): 129-130.
65. **Hari Kumar KB**, Sabu MC, Lima PS and Kuttan R (2004): Modulation of hematopoietic system and antioxidant enzymes by *Emblica officinalis* Gaertn and its protective role against γ -radiation induced damages in mice. *Journal of Radiation Research*. 45: 549-555.
66. **Hari Kumar KB** and Kuttan R (2004): Protective effect of an extract of *Phyllanthus amarus* against radiation induced damage in mice. *Journal of Radiation Research*. 45: 133-139.

Books edited

1. **Harikumar KB**. Complementary and alternative medicines in prostate cancer: A comprehensive approach (Series: Traditional Herbal Medicines for Modern Times). Published by CRC Press, USA in

2016 (ISBN 9781498729871)

URL: <https://www.taylorfrancis.com/books/9781315370156>

2. **Harikumar KB** and Kuttan R. *Phyllanthus* species: Scientific Evaluation and Medicinal Applications (Series: Traditional Herbal Medicines for Modern Times). Published by CRC Press, USA in 2011.
URL: <http://www.crcpress.com/product/isbn/9781439821442>

Chapters in book

1. Babu A, Mohammed S, **Harikumar KB** (2019): Anti-oxidant properties of curcumin: Impact on neurological disorders In " Curcumin for Neurological and Psychiatric Disorders, 1st Edition Neurochemical and Pharmacological Properties. Farooqui T, Farooqui A.A (Ed). Academic Press (Elsevier), pp 155-167
2. Mohammed, S and **Harikumar KB** (2017). Cancer Immunology of Syzygium cumini. In "The Genus Syzygium. Syzygium cumini and other under utilized species". Nair. K.N (Ed). CRC Press, USA pp.163-169.
3. Mohammed S, **Harikumar KB** (2017). Role of resveratrol in chemosensitization of cancer. In "Role of nutraceuticals in cancer chemosensitization". In Bharti AC and Aggarwal BB(Eds). Academic Press (Elsevier), USA. pp.61-76.
4. Aggarwal BB, **Harikumar KB**, Dey S. (2009) Prevention and Treatment of Neurodegenerative Diseases by Spice-Derived Phytochemicals. In Packer L, Sies H, Eggersdorfer M, Cadenas E (eds), Micronutrients and Brain Health, CRC Press, Boca Raton, Pages 281-307.
5. Preethi KC, **Harikumar KB**, Kuttan R (2009). Therapy for hepatic carcinoma using herbal drugs. In Mukherjee P (eds), Evaluation of Herbal Medicinal Products [Perspective on quality, safety and efficacy], Pharmaceutical Press, London, Pages 122-132.
6. Kunnumakkara AB, Anand P, **Harikumar KB**, Aggarwal BB. (2009) DNA damage and cancer chemoprevention by polyphenols. In Knasmuller S, DeMarini DM, Johnson IT, Gerhauser C (eds), Chemoprevention of cancer and DNA damage by dietary factors, 2009 WILEY-VCH Verlag GmbH & Co, Weinheim. Pages 455-482.
7. Kuttan R, Kuttan G, Sunila ES, Preethi KC, Nimita Venugopal C, **Hari Kumar KB**. (2008) An experimental evaluation to the anticancer activity of Homeopathic medicines. In Pushpangadan P, George V, Janardhanan KK (eds), Ethnopharmacology : Recent advances, Daya Publications, New Delhi. Pages 34-37.